Search clinical trials for: lisdexamfetamine dimesylate (SPD489)

Total 1323 results

Shire

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Chile, Australia, Argentina, United Kingdom
Shire

Completed

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

Schizophrenia and Predominant Negative Symptoms

United States
Shire

Completed

Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Terminated

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Completed

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

United States
Shire

Completed

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

Germany, Italy, Poland, Spain, Romania, Belgium, Hungary, Netherlands, Sweden, United Kingdom
Shire

Completed

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder (BED)

Binge Eating Disorder

United States
Shire

Completed

Open Label Extension in Adults With Binge Eating Disorder (BED)

Binge Eating Disorder

Spain, United States, Germany
Shire

Withdrawn

SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia (NSS)

Negative Symptoms of Schizophrenia
Shire

Completed

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Spain, Germany, Canada, Sweden
Shire

Completed

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

ADHD

Germany, Hungary, Italy, Poland, Sweden, United States, United Kingdom, Belgium, France
Shire

Completed

SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
Shire

Completed

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

Schizophrenia

United States
Shire

Completed

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Withdrawn

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Germany
Shire

Completed

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Binge Eating Disorder

United States, Spain, Germany, Sweden
Shire

Completed

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Healthy

United States
Shire

Terminated

Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Terminated

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Schizophrenia

United States
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Spain, Canada, Puerto Rico, Croatia, Mexico
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States, Canada, Germany, Hungary, Sweden
Shire

Completed

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States, Germany, Sweden, Poland, South Africa, Belgium, Czechia, Estonia, Finland, Hungary, Romania
Shire

Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Attention-deficit/Hyperactivity Disorder

United States
Shire

Terminated

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Major Depressive Disorder

United States, Spain, Germany, Puerto Rico, Canada, Estonia, South Africa, Czechia, Finland, Chile, Hungary, Mexico, Poland, Romania
Shire

Completed

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

Major Depressive Disorder

United States
Seattle Children's Hospital
Shire

Completed

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children (TMF)

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

Sleep Deprivation

United States
Shire

Completed

Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers

Healthy Volunteers

United States
Shire

Completed

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD Specifically With Executive Function Impairment

United States
Shire

Completed

Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Gregory Fabiano

Completed

Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD

Attention Deficit Disorder With Hyperactivity

United States
Aaron Keshen
Nova Scotia Health Authority

Terminated

Lisdexamfetamine for Adults With Bulimia Nervosa

Bulimia Nervosa

Canada
Clinical Study Centers, LLC
Shire

Completed

Effect of Vyvanse on Sleep in Children Aged 6-12 Years With Attention Deficit Hyperactivity Disorder (ADHD)

Sleep | Attention Deficit Hyperactivity Disorder

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrolling by invitation

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b)

Loss-of-control Eating | Obesity/Overweight

United States
Shire

Completed

A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD

United States
Shire

Completed

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

ADHD

United States
Kimberley Lakes
Shire

Completed

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading (VBHR)

Attention Deficit/Hyperactivity Disorder

United States
New River Pharmaceuticals
Shire

Completed

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity Disorders

United States
University Health Network, Toronto
Shire

Completed

To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II Disorder

Bipolar Disorder | Attention Deficit/Hyperactivity Disorder

Canada
University of Rhode Island
Lehigh University

Completed

Effects of LDX on Functioning of College Students With ADHD

Attention-deficit/Hyperactivity Disorder

United States
Rhodes Pharmaceuticals, L.P.
Purdue Pharma LP

Completed

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

Attention Deficit Hyperactivity Disorder

United States
New York State Psychiatric Institute

Completed

Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse

Attention Deficit Hyperactivity Disorder
Mclean Hospital
Shire

Completed

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

Major Depressive Disorder

United States
Shire

Completed

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Shire

Completed

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

ADHD

Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Seattle Children's Hospital

Completed

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

Attention Deficit/Hyperactivity Disorder (ADHD)

United States
North Dakota State University
Shire; Neuropsychiatric Research Institute, Fargo, North Dakota

Unknown

Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients

Lisdexamfetamine

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine

Obesity, Morbid

Norway

3

Subscribe